ImmunityBio IBRX
United StatesHealthcare · BiotechnologyUSD
12.75 USD (+30.8%)
4 analysts
Trading 2120.30 €Open account ↗
Lightyear0.90 €Open account ↗
N260.90 €Open account ↗
XTB1.00 €★ featured · affiliateOpen account ↗Trading 2120.30 €Open account ↗Lightyear0.90 €Open account ↗XTB1.00 €★ featured · affiliateOpen account ↗200.00 € order · cheapest cheapest available in your country iCompare all 22 brokers →What does it do?
ImmunityBio is a clinical-stage biotechnology company developing immunotherapies and oncology vaccines, primarily for cancers such as renal cell carcinoma and mesothelioma.
Key points
from its scores- ✓Strong growth10.0
- ✓Good share-price trend9.8
- ✓High-quality business9.5
- ✕Demanding valuation0.3
- ✕Little or no dividend0.5
AI analysis
bottom line, main risk, context and newsHigh-risk speculative stock: only suitable for investors who accept the possibility of total loss if the FDA does not approve its lead therapy.
ImmunityBio is a pre-revenue biotech with a -120% operating margin and negative FCF yield, whose value depends on FDA approval for its oncology therapy; the +235% 12-month momentum reflects speculative expectations, not current results.
The dominant risk is regulatory: FDA approval or rejection of its lead candidate (N-803) is a binary event that will determine the company's viability, given it has no revenue to sustain it.
Context and risks
Clinical-stage biotech with very negative operating margins and no revenue to cover its cost structure. The main risk is regulatory: it depends on FDA approval for its oncology therapy, a binary process that can sink or spike the stock. The high volatility (beta 9.25) and extreme momentum reflect a speculative valuation not backed by fundamentals.
Is ImmunityBio stock cheap or expensive?
at the analysis dateOn Price / sales, it trades 1,724% above the Healthcare median.
| Multiple | Company | Sector | Difference |
|---|---|---|---|
| Price / sales | 62.3 | 3.4 | +1,724% |
Sector: median of the 217 Healthcare companies analysed. In bold, the multiples used for the comparison.
Valuation score: 0.3 out of 10 (median for Healthcare: 4.7).
Average analyst target: 12.75 USD, +30.8% versus the price.
A premium can be justified if the company is of higher quality or grows faster than its sector: Quality / Moat 9.5 (sector 5.5), Growth 10.0 (sector 6.6).
Work out its fair value yourself →How much would you have made investing every month? →
Comparing it with its sector does not say whether it is a good buy: this is not investment advice.
Score by category
0 to 10 · hover overtap each one to see what it measuresKey metrics
at the analysis date · compared with the Healthcare medianValuation
- Forward P/E
- −69.6
- EV / EBITDA
- −47.6
- Price / book
- −9.8
- Price / sales
- 62.3
- Market cap
- 10.3B USD
- Enterprise value
- 11.2B USD
Profitability
- ROA
- −30.5%
- Gross margin
- 99.3%
- Operating margin
- −120.4%
- Net margin
- 0.0%
- Free cash flow
- −186.6M USD
- FCF yield
- −1.8%
Solvency
- Total debt
- 1.2B USD
- Net debt
- 871.0M USD
- Cash
- 357.4M USD
- EBITDA
- −235.3M USD
- Net debt / EBITDA
- −3.70
- Current ratio
- 5.72
- Quick ratio
- 5.36
Growth
- Revenue growth
- +93.9%
- EPS (TTM)
- −0.96 USD
- EPS (forward)
- −0.14 USD
Dividend
- Dividend yield
- 0.0%
Risk and market
- Beta
- 0.03
- Analyst consensus
- Strong buy (4)
- Target price
- 12.75 USD
- 52-week range
- 1.95 – 12.43
Recent news
All IBRX news →Compare it with its sector
All 217 in Healthcare →Frequently asked questions about ImmunityBio
Is ImmunityBio stock cheap or expensive?
On Price / sales, it trades 1,724% above the Healthcare median. Valuation score: 0.3 out of 10 (median for Healthcare: 4.7). Average analyst target: 12.75 USD, +30.8% versus the price. This is not investment advice.
What score does ImmunityBio get on MeridIAn Screener?
It scores 6.5 out of 10, rank 541 of 2,130 (better than 72% of the companies analysed). Its strongest category is Growth (10.0) and its weakest, Valuation (0.3). Analysis of 08/10/2026.
How much is ImmunityBio worth on the stock market?
Its market capitalisation is 10.3B USD and its enterprise value, debt included, is 11.2B USD.
How much debt does ImmunityBio have?
Its net debt (debt minus cash) is 871.0M USD.
Does ImmunityBio pay a dividend?
It pays no dividend, or almost none.
How has ImmunityBio stock performed over the last year?
It has risen 313.1% over the last year, excluding dividends. Over the last 52 weeks it has traded between 1.95 and 12.43 USD. Past performance does not guarantee future results.
What do analysts think of ImmunityBio?
4 analysts cover it; their average recommendation is “Strong buy” and their average target is 12.75 USD (+30.8% versus the price). It is an estimate, not market data.